{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:02:28Z","timestamp":1790805748419,"version":"4.1.0"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Baylor Research Institute"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    In pharmacokinetic\/pharmacodynamic models of pulmonary\n                    <jats:named-content content-type=\"genus-species\">Mycobacterium abscessus<\/jats:named-content>\n                    complex, the recommended macrolide-containing combination therapy has poor kill rates. However, clinical outcomes are unknown. We searched the literature for studies published between 1990 and 2017 that reported microbial outcomes in patients treated for pulmonary\n                    <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n                    disease. A good outcome was defined as sustained sputum culture conversion (SSCC) without relapse. Random effects models were used to pool studies and estimate proportions of patients with good outcomes. Odds ratios (OR) and 95% confidence intervals (CI) were computed. Sensitivity analyses and metaregression were used to assess the robustness of findings. In 19 studies of 1,533 patients, combination therapy was administered to 508 patients with\n                    <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n                    subsp.\n                    <jats:named-content content-type=\"genus-species\">abscessus<\/jats:named-content>\n                    , 204 with\n                    <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n                    subsp.\n                    <jats:named-content content-type=\"genus-species\">massiliense<\/jats:named-content>\n                    , and 301 with\n                    <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n                    with no subspecies specified. Macrolide-containing regimens achieved SSCC in only 77\/233 (34%) new\n                    <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n                    subsp.\n                    <jats:named-content content-type=\"genus-species\">abscessus<\/jats:named-content>\n                    patients versus 117\/141 (54%)\n                    <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n                    subsp.\n                    <jats:named-content content-type=\"genus-species\">massiliense<\/jats:named-content>\n                    patients (OR, 0.108 [95% CI, 0.066 to 0.181]). In refractory disease, SSCC was achieved in 20% (95% CI, 7 to 36%) of patients, which was not significantly different across subspecies. The estimated recurrent rates per month were 1.835% (range, 1.667 to 3.196%) for\n                    <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n                    subsp.\n                    <jats:named-content content-type=\"genus-species\">abscessus<\/jats:named-content>\n                    versus 0.683% (range, 0.229 to 1.136%) for\n                    <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n                    subsp.\n                    <jats:named-content content-type=\"genus-species\">massiliense<\/jats:named-content>\n                    (OR, 6.189 [95% CI, 2.896 to 13.650]). The proportion of patients with good outcomes was 52\/223 (23%) with\n                    <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n                    subsp.\n                    <jats:named-content content-type=\"genus-species\">abscessus<\/jats:named-content>\n                    versus 118\/141 (84%) with\n                    <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n                    subsp.\n                    <jats:named-content content-type=\"genus-species\">massiliense<\/jats:named-content>\n                    disease (OR, 0.059 [95% CI, 0.034 to 0.101]).\n                    <jats:named-content content-type=\"genus-species\">M. abscessus<\/jats:named-content>\n                    subsp.\n                    <jats:named-content content-type=\"genus-species\">abscessus<\/jats:named-content>\n                    pulmonary disease outcomes with the currently recommended regimens are atrocious, with outcomes similar to those for extensively drug-resistant tuberculosis. Therapeutically, the concept of nontuberculous mycobacteria is misguided. There is an urgent need to craft entirely new treatment regimens.\n                  <\/jats:p>","DOI":"10.1128\/aac.01206-17","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T20:40:16Z","timestamp":1502743216000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":171,"title":["Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence"],"prefix":"10.1128","volume":"61","author":[{"given":"Jotam G.","family":"Pasipanodya","sequence":"first","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics (CIDRET), Baylor Research Institute, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ogbonna","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics (CIDRET), Baylor Research Institute, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz E.","family":"Ferro","sequence":"additional","affiliation":[{"name":"Department of Public Health and Community Medicine, Universidad ICESI, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesham","family":"Magombedze","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics (CIDRET), Baylor Research Institute, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikant","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics (CIDRET), Baylor Research Institute, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devyani","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics (CIDRET), Baylor Research Institute, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics (CIDRET), Baylor Research Institute, Dallas, Texas, USA"},{"name":"Department of Medicine, University of Cape Town, Observatory, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr578"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.03.006"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-241"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60632-7"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/cid\/ciw877","article-title":"Two-phase hospital-associated outbreak of Mycobacterium abscessus: investigation and mitigation","volume":"64","author":"Baker AW","year":"2017","unstructured":"Baker AW LewisSS AlexanderBD ChenLF WallaceRJ Jr Brown-ElliottBA IsaacsPJ PickettLC PatelCB SmithPK ReynoldsJM EngelJ WolfeCR MilanoCA SchroderJN DavisRD HartwigMG StoutJE StrittholtN MaziarzEK SaulloJH HazenKC WalczakRJ Jr VasireddyR VasireddyS McKnightCM AndersonDJ SextonDJ. 2017. Two-phase hospital-associated outbreak of Mycobacterium abscessus: investigation and mitigation. Clin Infect Dis64:902\u2013911.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-1297"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00402-06"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.12.003"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201111-2016OC"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200805-686OC"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1099\/ijsem.0.001376"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000327"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200905-0704OC"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201003-0395OC"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00990-16"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02821-15"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03112-15"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02505-16"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201508-529OC"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/147.5.1271"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01175-12"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq237"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw724"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.05.003"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.12.012"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1689-6"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0700OC"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201307-231OC"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw723"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2014.08.005"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2009.08.016"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku062"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02052-16"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62675-6"},{"key":"e_1_3_3_37_2","volume-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"Gumbo T","year":"2010","unstructured":"Gumbo T . 2010. General principals of antimicrobial therapy. InBruntonLL ChabnerBA KnollmannBC (ed), Goodman and Gilman's the pharmacological basis of therapeutics. McGraw Hill Medical, New York, NY."},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx311"},{"key":"e_1_3_3_39_2","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"3","author":"Moher D","year":"2009","unstructured":"Moher D LiberatiA TetzlaffJ AltmanDG. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med3:e123\u2013e130.","journal-title":"Open Med"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1752"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dym018"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/2049-3258-72-39"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.11.1054"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01206-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01206-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T18:51:06Z","timestamp":1750791066000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01206-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1128\/AAC.01206-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01206-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"2017-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01206-17"}}